Topics
Ozempic
Every story about Ozempic, updated as news breaks.
What to know
- FDA warns of NAION risk with GLP‑1 receptor agonists Nov 10
- Over 125 trials show about 6 cases per 100,000 users after one year Nov 10
- FDA added new warnings to Ozempic, Zepbound, Wegovy and Mounjaro for NAION risk. Nov 9
- Patients should watch for sudden vision loss or blurred vision and report changes immediately. Nov 9
- Retatrutide reduced A1C 2.2% after 80 weeks, higher than Ozempic’s 1.8%. Oct 28
Timeline
- Nov 10, 2026
- Nov 9, 2026
- Oct 28, 2026


